Paraneoplastic hypereosinophilia in a patient with peripheral T cell lymphoma, not otherwise specified

Authors

  • Minodora Desmirean
  • Dalma Deak
  • Ioana Rus
  • Delia Dima
  • Sabina Iluta
  • Alexandra Preda
  • Tiberiu Modovan
  • Andrei Roman
  • Ciprian Tomuleasa
  • Bobe Petrushev

DOI:

https://doi.org/10.15386/mpr-1347

Keywords:

hypereosinophilia, paraneoplastic syndrome, peripheral T cell lymphoma - NOS

Abstract

Under normal physiological conditions, the bone marrow (BM) will have between 1% and 6% eosinophils, translating into a peripheral count of 0.05 – 0.5 x109 /L eosinophils in the blood smear. This process is coordinated by transcription factors with specific roles in differentiation and activation. Secondary eosinophilia may be a paraneoplastic syndrome, related to the presence of a subsequent malignancy, as presented in this case report. Such paraneoplastic manifestations should be addressed properly in order for the patient to receive the best treatment of choice. Even if eosinophilia was associated with B-cell malignancies before, this is a report associating this symptom to a peripheral T-cell lymphoma, not other specified, thus emphasizing the importance of a complex approach for the management of the oncological patient.

 

Downloads

Published

2019-09-23

How to Cite

1.
Desmirean M, Deak D, Rus I, Dima D, Iluta S, Preda A, Modovan T, Roman A, Tomuleasa C, Petrushev B. Paraneoplastic hypereosinophilia in a patient with peripheral T cell lymphoma, not otherwise specified. Med Pharm Rep [Internet]. 2019 Sep. 23 [cited 2025 Oct. 5];92(4):421-6. Available from: https://medpharmareports.com/index.php/mpr/article/view/1347

Issue

Section

Case Report